A Phase IIa study of tisotumab vedotin (HuMax (R)-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer: updated safety and efficacy.
Concin, N Vergote, I Lassen, U De Bono, J Drew, Y Machiels, J Nielsen, D Arkenau, T Forster, M
Concin, N
Vergote, I
Lassen, U
De Bono, J
Drew, Y
Machiels, J
Nielsen, D
Arkenau, T
Forster, M
Citations
Altmetric:
Abstract
Description
Date
2017
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
A Phase IIa study of tisotumab vedotin (HuMax (R)-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer: updated safety and efficacy. 2017, 27: 1971 Int J Gynecol Cancer